Bluepharma

Bluepharma

Coimbra, Portugal· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $65M

Overview

Bluepharma is a private Portuguese pharmaceutical group founded in 2001, built on the acquisition of a former Bayer plant. It has evolved from a manufacturing operation into an integrated CRDMO with over 650 employees, 20 innovative group companies, and a strong export focus (89% export rate). The company's core business spans R&D, contract development and manufacturing (CDMO) for high-potency products, and the commercialization of its own portfolio, supported by proprietary technologies like BlueOS® and ONConcept®.

Small MoleculesDrug Delivery

Technology Platform

Proprietary drug delivery system (BlueOS®) and specialized manufacturing platform for high-potency/complex products (ONConcept®).

Funding History

2
Total raised:$65M
Series C$40M
Debt$25M

Opportunities

The growing global outsourcing trend for complex small molecule and high-potency drug manufacturing presents a major opportunity for its expanded CDMO capacity.
Expansion into emerging markets like Angola, Mozambique, and Brazil through local subsidiaries offers significant commercial growth potential for its product portfolio and services.

Risk Factors

Key risks include dependence on the competitive CDMO market, vulnerability to partner pipeline failures, and stringent regulatory compliance requirements for manufacturing.
A concentrated focus on small molecules may pose a strategic risk if the industry shifts heavily towards biologics and advanced therapies.

Competitive Landscape

Bluepharma competes in the European and global CDMO space against larger players like Lonza, Catalent, and Recipharm, as well as regional specialists. Its differentiation lies in its integrated 'R&D to market' model, proprietary drug delivery technologies, specialized high-potency capabilities, and its position as a cost-competitive EU-based manufacturer with strong regulatory credentials.